InMed Pharmaceuticals Files 8-K
Ticker: INM · Form: 8-K · Filed: Oct 24, 2024 · CIK: 1728328
Sentiment: neutral
Topics: corporate-filing, regulation-fd
TL;DR
InMed Pharma filed an 8-K on Oct 24th, mostly corporate details, no major news yet.
AI Summary
InMed Pharmaceuticals Inc. filed an 8-K on October 24, 2024, reporting a Regulation FD Disclosure and Financial Statements and Exhibits. The filing details the company's principal executive offices located at Suite 1445 - 885 W. Georgia Street, Vancouver, B.C., Canada, V6C 3E8, and provides their telephone number as (604) 669-7207. No specific financial figures or material events were detailed in the provided excerpt.
Why It Matters
This filing serves as an official notification to the SEC and the public regarding InMed Pharmaceuticals' corporate information and regulatory compliance.
Risk Assessment
Risk Level: low — The filing is a routine corporate disclosure and does not contain information that inherently increases risk.
Key Players & Entities
- InMed Pharmaceuticals Inc. (company) — Filer
- October 24, 2024 (date) — Date of Report
- Vancouver, B.C. Canada (location) — Principal Executive Offices
- (604) 669-7207 (phone_number) — Company Telephone Number
FAQ
What is the primary purpose of this 8-K filing for InMed Pharmaceuticals Inc.?
The primary purpose of this 8-K filing is to report a Regulation FD Disclosure and to provide Financial Statements and Exhibits, as well as update corporate information.
When was the earliest event reported in this filing?
The earliest event reported in this filing was on October 24, 2024.
Where are InMed Pharmaceuticals Inc.'s principal executive offices located?
InMed Pharmaceuticals Inc.'s principal executive offices are located at Suite 1445 - 885 W. Georgia Street, Vancouver, B.C. Canada, V6C 3E8.
What is the company's telephone number as listed in the filing?
The company's telephone number, including area code, is (604) 669-7207.
What is the Commission File Number for InMed Pharmaceuticals Inc.?
The Commission File Number for InMed Pharmaceuticals Inc. is 001-39685.
Filing Stats: 544 words · 2 min read · ~2 pages · Grade level 10.5 · Accepted 2024-10-24 15:57:39
Filing Documents
- ea0218583-8k_inmed.htm (8-K) — 37KB
- ea021858301ex99-1_inmed.htm (EX-99.1) — 18KB
- ex99-1_001.jpg (GRAPHIC) — 5KB
- 0001213900-24-090365.txt ( ) — 237KB
- inm-20241024.xsd (EX-101.SCH) — 3KB
- inm-20241024_lab.xml (EX-101.LAB) — 33KB
- inm-20241024_pre.xml (EX-101.PRE) — 22KB
- ea0218583-8k_inmed_htm.xml (XML) — 4KB
01. Financial Statements and Exhibits
Item 9.01. Financial Statements and Exhibits. (d) Exhibits: The following exhibits shall be deemed to be furnished, and not filed: Exhibit No. Description 99.1 News release, dated October 24, 2024 104 Cover Page Interactive Data File (embedded within the Inline XBRL document and included as Exhibit 101) 1
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. INMED PHARMACEUTICALS INC. Date: October 24, 2024 By: /s/ Eric A Adams Eric A Adams President & CEO 2